Neutrophil Gelatinase-Associated Lipocalin and Contrast-Induced Acute Kidney Injury

Circ Cardiovasc Interv. 2015 Sep;8(9):e002673. doi: 10.1161/CIRCINTERVENTIONS.115.002673.

Abstract

Background: Neutrophil gelatinase-associated lipocalin (NGAL) is an early marker of acute kidney injury (AKI).

Methods and results: Urine NGAL and serum NGAL (sNGAL) were assessed at 2, 6, 24, and 48 hours after contrast media (CM) exposure in 458 high-risk patients (development set). Optimal thresholds in predicting contrast-induced AKI (serum creatinine [sCr] increase ≥0.3 mg/dL at 48 hours after CM administration) were identified. Major adverse events (MAE; death, dialysis, nonfatal myocardial infarction, sustained kidney injury, and myocardial revascularization) at 1 year were assessed. In the development set, optimal thresholds for contrast-induced AKI occurred at 6 hours for both urine NGAL (≥20 ng/mL; 97% negative predictive value and 27% positive predictive value) and sNGAL (≥179 ng/mL; 93% negative predictive value and 20% positive predictive value). Furthermore, sNGAL ≥179 ng/mL at 6 hours was an independent predictor of 1-year MAE. 1-year MAE occurred in 27/198 patients (13.5%) with sNGAL <179 ng/mL and sCr <0.3 mg/dL, in 57/193 (29.5%) patients with only sNGAL ≥179 ng/mL, and in 37/67 (55%) patients with sCr ≥0.3 mg/dL. In additional 253 patients (validation set), no patient with urine NGAL <20 ng/mL or sNGAL <179 ng/mL at 6 hours developed contrast-induced AKI. Furthermore, 6/68 (9%) patients with sNGAL <179 ng/mL and sCr increase <0.3 mg/dL had 1-year MAE versus 17/57 (30%) patients with sNGAL ≥179 ng/mL and sCr increase <0.3 mg/dL and 8/16 (50%) patients with sCr increase ≥0.3 mg/dL.

Conclusions: Urine NGAL <20 ng/mL and sNGAL <179 ng/mL at 6 hours are reliable markers for ruling out contrast-induced AKI. sNGAL ≥179 ng/mL at 6 hours predicts 1-year MAE.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01098032.

Keywords: NGAL; contrast media; kidney; kidney disease; prognostic factor.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / diagnosis*
  • Acute Kidney Injury / metabolism
  • Acute-Phase Proteins / urine
  • Aged
  • Aged, 80 and over
  • Angiography
  • Angioplasty
  • Biomarkers / blood
  • Biomarkers / urine
  • Contrast Media / adverse effects*
  • Creatinine / blood
  • Female
  • Humans
  • Lipocalin-2
  • Lipocalins / blood*
  • Lipocalins / urine
  • Male
  • Proto-Oncogene Proteins / blood*
  • Proto-Oncogene Proteins / urine
  • Renal Insufficiency, Chronic / complications*
  • Triiodobenzoic Acids / adverse effects*

Substances

  • Acute-Phase Proteins
  • Biomarkers
  • Contrast Media
  • LCN2 protein, human
  • Lipocalin-2
  • Lipocalins
  • Proto-Oncogene Proteins
  • Triiodobenzoic Acids
  • Creatinine
  • iodixanol

Associated data

  • ClinicalTrials.gov/NCT01098032